Peyto Exploration & Development Corp

TSX:PEYCanadaView on OTC Pink - Current Information

Nov 12, 2024

Show headlines and story abstract

• MT Newswires Stocks To Watch: Eupraxia Pharmaceuticals and i-80 Gold. Also Conifex, Crown; Dream Unlimited; DCM; NGEx; Peyto; Primaris REIT; VIQ Solutions, from 8:37PM ET on Tuesday Nov 12, 2024 by MT Newswires

  8:37PM ET on Tuesday Nov 12, 2024 by MT Newswires
  Companies Mentioned: PEY, VQS, NGEX, DRM, EPRX, IAU, CFF, DCM, CRWN
  08:37 PM EST, 11/12/2024 (MT Newswires) -- Eupraxia Pharmaceuticals Inc. (TSX and NASDAQ: EPRX), a clinical-stage biotechnology company developing precision drug delivery for indications with significant unmet need, announced additional "positive" c...

• Peyto Reports Strong Third Quarter Results and Preliminary 2025 Capital Program, from 7:14PM ET on Tuesday Nov 12, 2024 by Dow Jones

  7:14PM ET on Tuesday Nov 12, 2024 by Dow Jones
  Companies Mentioned: PEY
  
  (1) This press release contains certain non-GAAP and other financial measures to analyze financial performance, financial position, and cash flow including, but not limited to "operating margin", "profit margin", "return on capital", "return on equity", "netback", "funds from operations", "free funds flow", "total cash costs", and "net debt". These non-GAAP and other financial measures do not have any standardized meaning prescribed under IFRS and therefore may not be comparable to similar measures presented by other entities. The non-GAAP and other financial measures should not be considered to be more meaningful than GAAP measures which are determined in accordance with IFRS, such as earnings, cash flow from operating activities, and cash flow used in investing activities, as indicators of Peyto's performance. See "Non-GAAP and Other Financial Measures" included at the end of this press release and in Peyto's most recently filed MD&A for an explanation of these financial measures and reconciliation to the most directly comparable financial measure under IFRS.